Form D Worth Mentioning: Histogenics $30.00 million Financing. Adam Gridley Released Oct 12 D Form

Health Care Histogenics Corp - Adam Gridley

Histogenics Financing

Histogenics Corp, Corporation just had published form D announcing $30.00 million equity financing. This is a new filing. Histogenics was able to sell $30.00 million. That is 100.00% of the financing offer. The total financing amount was $30.00 million. The offering form was filed on 2016-10-12. The reason for the financing was: unspecified.

Histogenics is based in Massachusetts. The firm’s business is Other Health Care. The form was submitted by Adam Gridley CEO. The company was incorporated more than five years ago. The filler’s address is: 830 Winter Street, 3Rd Floor, Waltham, Ma, Massachusetts, 02451. Adam Gridley is the related person in the form and it has address: C/O Histogenics Corporation, 830 Winter Street, 3Rd Floor, Waltham, Ma, Massachusetts, 02451. Link to Histogenics Filing: 000167140016000002.

Analysis of Histogenics Offering

On average, startups in the Other Health Care sector, sell 68.60% of the total offering amount. Histogenics sold 100.00% of the offering. Could this mean that the trust in Histogenics is high? The average fundraising size for companies in the Other Health Care industry is $1.16 million. The total amount raised is 2,486.21% bigger than the average for companies in the Other Health Care sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Histogenics Also

The Form D signed by Adam Gridley might help Histogenics Corp’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment